Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have earned an average rating of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $10.80.

SANA has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Sana Biotechnology in a research note on Tuesday. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a report on Tuesday. Finally, Jefferies Financial Group started coverage on shares of Sana Biotechnology in a research note on Friday, March 14th. They set a “buy” rating and a $7.00 price target on the stock.

Sana Biotechnology Stock Performance

Shares of SANA opened at $2.28 on Friday. The stock has a market capitalization of $509.05 million, a P/E ratio of -1.63 and a beta of 1.63. Sana Biotechnology has a 1 year low of $1.52 and a 1 year high of $10.50. The company’s fifty day moving average is $3.06 and its two-hundred day moving average is $3.20.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. Sell-side analysts predict that Sana Biotechnology will post -1.16 EPS for the current year.

Insider Activity

In other news, insider Fmr Llc sold 290,912 shares of the stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the sale, the insider now directly owns 4,541,511 shares in the company, valued at $29,474,406.39. This represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 31.10% of the company’s stock.

Institutional Investors Weigh In On Sana Biotechnology

Large investors have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Sana Biotechnology by 10.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 279,282 shares of the company’s stock valued at $455,000 after acquiring an additional 25,383 shares in the last quarter. Vident Advisory LLC raised its stake in Sana Biotechnology by 42.3% in the 4th quarter. Vident Advisory LLC now owns 43,291 shares of the company’s stock valued at $71,000 after purchasing an additional 12,861 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in Sana Biotechnology by 45.3% in the 4th quarter. Squarepoint Ops LLC now owns 178,431 shares of the company’s stock valued at $291,000 after purchasing an additional 55,625 shares in the last quarter. Two Sigma Advisers LP boosted its stake in shares of Sana Biotechnology by 677.0% during the 4th quarter. Two Sigma Advisers LP now owns 209,000 shares of the company’s stock worth $341,000 after purchasing an additional 182,100 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in shares of Sana Biotechnology by 228.4% during the 4th quarter. Two Sigma Investments LP now owns 480,298 shares of the company’s stock worth $783,000 after purchasing an additional 334,042 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.